Successful outcome of DIC and life-threatening bleeding in a toddler with neuroblastoma treated with recombinant activated factor VII

Internal and Emergency Medicine

Volumn 3, Issue 2, 2008, Pages 171-173

  Hatzipantelis, Emmanouil S ^a   Gombakis, Nikolaos ^b   Sidi, Vasiliki ^a   Papakonstantinou, Evgenia ^a   Koliouskas, Dimitrios E ^a  

^a Aristotle University of Thessaloniki   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLOOD CLOTTING FACTOR 7A; COAGULATING AGENT; RECOMBINANT PROTEIN;

ARTICLE; BLEEDING; CASE REPORT; CHEMICALLY INDUCED DISORDER; DISSEMINATED INTRAVASCULAR CLOTTING; HUMAN; INFANT; MALE; NEUROBLASTOMA; TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COAGULANTS; DISSEMINATED INTRAVASCULAR COAGULATION; FACTOR VIIA; HEMORRHAGE; HUMANS; INFANT; MALE; NEUROBLASTOMA; RECOMBINANT PROTEINS; TIME FACTORS; TREATMENT OUTCOME;

EID: 43749123410     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-008-0104-8     Document Type: Article

References (14)

1. Sallah S, Husain A, Nguyen-Nam P (2004) Recombinant activated factor VII in patients with cancer and hemorrhagic disseminated intravascular coagulation. Blood Coagul Fibrinolysis 15(7):577-582
2. Malone DL, Dune J, Tracy JK, Putnam AT, Scalea TM, Napolitano LM (2003) Blood transfusion, independent of shock severity, is associated with worse outcome in trauma. J Trauma 54:898-907
3. Von Depka M. Novoseven (2002) Mode of action and use in acquired haemophilia. Intensive Care Med 28:222-227
4. Kenet G, Walden R, Eldad A, Martinowitz U (1999) Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 354:1879
5. Martinowitz U, Kenet G, Segal E, Luboshitz J, Lubetsky A, Ingerslev J, Lynn M (2001) Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 51:431-439
6. Grounds M (2003) Recombinant factor VIIa (rFVIIa) and its use in severe bleeding in surgery and trauma: a review. Blood Rev 17:11-21
7. Friederich PW, Henny CP, Messelink FJ, Geerdink MG, Keller T, Kurth KH, Buller HR, Levi M (2003) Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 361:201-205
8. Deveras RA, Kessler CM (2002) Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med 137:884-888
9. Hedner U. Recombinant factor VIIa (Novoseven) as a hemostatic agent. Dis Mon 49:39-48
10. Roberts HR, Monroe DM, White GC (2004) The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 104:3858-3864
11. Hoffman M (2003) A cell-based model of coagulation and the role of factor VIIa. Blood Rev 17(Suppl 1):1-5
12. Roberts HR (2001) Factor VIIa and the safety of treatment. Semin Hematol 38(suppl 12):48-50
13. Levi M (2003) Safety of recombinant factor VIIa. TATM 5:11-14
14. Martinowitz U, Michaelson M (2005) Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli multidisciplinary rFVIIa task force. J Thromb Haemost 3:640-648